Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

CAPS Rating: 2 out of 5

Discovers, develops and intend to commercialize drugs for the treatment of neurological and endocrine-related diseases and disorders. Product candidates will target insomnia, anxiety, depression, cancer, diabetes, and multiple sclerosis.

Recs

0
Player Avatar cashsage (30.40) Submitted: 6/8/2010 1:05:13 PM : Underperform Start Price: $4.15 NBIX Score: -31.84

NBIX has a too high valuation compared to its sales potential. It is also loss making at least until 2011. Its stock price may be more than halved.

Featured Broker Partners


Advertisement